Sanofi SA (SNY)
28 Jun 2016
* Sanofi sounding out Medivation shareholders as it prepares to raise bid- CNBC (Bengaluru Newsroom: +1 646 223 8780)
* Icagen says will retain majority of scientists working at Tucson site in transition
June 24 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:
Medivation Inc said shareholder advisory firm Glass Lewis & Co has recommended the cancer drug maker's stockholders to not support Sanofi SA's efforts to replace the company's board members.
June 24 Medivation Inc said shareholder advisory firm Glass Lewis & Co has recommended the cancer drug maker's stockholders to not support Sanofi SA's efforts to replace the company's board members.
Drug developer Inovio Pharmaceuticals Inc and its partner GeneOne Life Sciences Inc said they had received approval from U.S. regulators to start an early stage human trial testing their Zika vaccine.
June 20 Drug developer Inovio Pharmaceuticals Inc and its partner GeneOne Life Sciences Inc said they had received approval from U.S. regulators to start an early stage human trial testing their Zika vaccine.
BRIEF-Sanofi announces expiration of Hart-Scott-Rodino waiting period for proposed acquisition of Medivation
* Sanofi announces expiration of hart-scott-rodino waiting period regarding proposed acquisition of medivation Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
NEW YORK, June 13 French drugmaker Sanofi and its takeover target Medivation Inc on Monday said they had filed official materials with the U.S. Securities and Exchange Commission, as their $9.3 billion battle advances to the next phase.
PARIS French drugmaker Sanofi said on Monday that it had filed a request with U.S. authorities to remove the board of Medivation and replace it with eight independent candidates as it seeks to acquire the cancer drug company.
|Abbott Laboratories (ABT.N)||$37.56||+0.61|
|AstraZeneca plc (AZN.L)||4,273.50p||--|
|Bristol-Myers Squibb Co (BMY.N)||$72.01||+1.69|
|Bristol-Myers Squibb Co (BMYMP.PK)||$1,231.90||--|
|Eli Lilly and Co (LLY.N)||$75.15||+0.26|
|GlaxoSmithKline plc (GSK.L)||1,514.00p||--|
|Merck & Co., Inc. (MRK.N)||$55.58||+0.27|
|Novartis AG (NOVN.S)||CHF77.45||--|
|Novo Nordisk A/S (NOVOb.CO)||kr.347.50||+5.60|
|Roche Holding Ltd. (ROG.S)||CHF246.20||--|
Earnings vs. Estimates
Analyst Research Reports
Provider : New Constructs, LLC
Sanofi-Aventis - Finlabo Research Equity Report: Fundamental and Technical Analysis and 6 months performance forecast
Provider : Finlabo SIM Spa
Trading Report for (SNY). A detailed report, including free correlated market analysis, and updates.
Provider : Stock Traders Daily
Provider : ValuEngine, Inc.
Provider : S&P Capital IQ – STARS Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.